375 related articles for article (PubMed ID: 31333088)
1. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
3. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
5. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Dumasia R; Eagle KA; Kline-Rogers E; May N; Cho L; Mukherjee D
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):377-86. PubMed ID: 16248830
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
7. The mode of action of thiazolidinediones.
Hauner H
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
[TBL] [Abstract][Full Text] [Related]
8. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
9. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
10. [PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].
Scheen AJ; Paquot N
Rev Med Liege; 2005 Feb; 60(2):89-95. PubMed ID: 15819371
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
12. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
13. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
14. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
[TBL] [Abstract][Full Text] [Related]
15. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
Gelman L; Feige JN; Desvergne B
Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
18. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
Benz V; Kintscher U; Foryst-Ludwig A
Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
[TBL] [Abstract][Full Text] [Related]
19. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
20. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
